Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Recruiting now · Phase 1/Phase 2
Conditions studied: Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
In brief
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Key facts
- Study ID
- NCT04198766
- Run by
- Inhibrx Biosciences, Inc
- People needed
- 340
- Starts
- 2019-12-10
- Expected to finish
- 2033-07-01
- Last updated by the study team
- 2026-07-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mid Florida Hematology and Oncology Center — Orange City, Florida, United States (enrolling)
- Nebraska Cancer Specialists — Omaha, Nebraska, United States (enrolling)
- Winship Cancer Institute - Emory University — Atlanta, Georgia, United States (enrolling)
- Los Angeles Cancer Network — Glendale, California, United States (enrolling)
- California Research Institute — Los Angeles, California, United States (enrolling)
- Norton Cancer Institute — Louisville, Kentucky, United States (enrolling)
- Valkyrie Clinical Trials — Los Angeles, California, United States (enrolling)
- Henry Ford Cancer Institute — Detroit, Michigan, United States (enrolling)
- Valkyrie Clinical Trials — Murrieta, California, United States (enrolling)
- Providence Medical Foundation — Santa Rosa, California, United States (enrolling)
- The University of Texas Health Science Center at Tyler — Tyler, Texas, United States (enrolling)
- Clermont Oncology Center — Clermont, Florida, United States (enrolling)
- City of Hope — Duarte, California, United States (enrolling)
- Renovatio Clinical - El Paso — El Paso, Texas, United States
- NEXT Oncology — San Antonio, Texas, United States
- Renovatio Clinical — The Woodlands, Texas, United States
- Virginia Cancer Specialists — Fairfax, Virginia, United States
- Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States
- Curie Oncology — Singapore, Singapore
- Icon Cancer Centre Farrer Park — Singapore, Singapore
- Icon Cancer Centre Mount Alvernia — Singapore, Singapore
- The Catholic University of Korea, St. Vincent's Hospital — Gyeonggi-do, South Korea
- Asan Medical Center — Seoul, South Korea
- Severance Hospital, Yonsei University Health System — Seoul, South Korea
- The Catholic University of Korea Seoul St. Mary's Hospital, — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.